Cannabis Strain from Invictus' AB Laboratories Now For Sale on Canopy Growth Corporation's Tweed Sales Platform
May 11 2018 - 9:31AM
InvestorsHub NewsWire
Vancouver, BC -- May 11, 2018 --
InvestorsHub NewsWire -- INVICTUS MD
STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA: 8IS1) is pleased to
announce that cannabis from the company’s AB Laboratories Inc.
(AB Labs) is now is available for purchase through
Canopy Growth Corporation’s (TSX: WEED) Tweed Main
Street online store and to-date AB Labs has transferred 172 KG of
product to Canopy.
The strain Super Critical is available now as part of Tweed’s elite
CraftGrow line, and AB Labs anticipates shipping their other
strains in the near future.
“Canadian medical cannabis patients
value product diversity and we’re committed to offering them an
industry leading curated lineup from Tweed and our CraftGrow
partners,” said Mark Zekulin, President, Canopy Growth. “We’re
excited to welcome AB Labs product as the newest CraftGrow addition
to the Tweed Main Street online store”.
“The Canadian cannabis industry is diverse, dynamic and thriving,
with valuable partnerships being forged every day,” said Invictus
founder and CEO Dan Kriznic. “Our collaboration with Canopy has
already been enormously fruitful and rewarding. We look forward to
working closely with this model of entrepreneurial fitness and
efficiency as Canada’s commercial cannabis market develops in
coming months and years. I’m pleased to report that Invictus
remains on track for achieving its substantial cultivation and
harvest goals across 2018, and delivers more and more strains and
cannabis volume into Canada's thriving consumer marketplace as
Canada approaches legalization of the adult market. To further
accommodate this the Company has developed a multifaceted sales
strategy aimed to target each channel for sales and distribution
such as establishing supply agreements and product calls with
provincial governments and licensed producers, developing retail
storefronts across Western Canada, and continuing to focus on the
medical cannabis sector.”
Tweed’s highly curated CraftGrow line works only with top producers
cultivating Canada’s finest cannabis, and AB Labs is honored to
have been the second cultivator to successfully transfer cannabis
products to be sold though the e-commerce platform.
The Super Critical strain from AB Labs available on the platform is
a high-yielding 50/50 hybrid of sativa and indica, a mix of Big
Bud, Skunk and White Widow. The combination of exceptional yield
plus superb flower makes it a favorite among growers.
AB Labs continues to make continuous
progress on its 40,000 square foot Phase 2 facility, which once
completed AB Labs will total 56,000 square foot of production
capability. To-date in Phase 2 the interior demolition has
been completed, cleaned and sanitized and all upgrades to the
electrical and HVAC systems have also been completed. Construction
of the mezzanine level has begun and overall progress is according
to plan.
About Invictus
Invictus owns and operates cannabis companies in Canada with the
vision of producing a variety of high quality and low cost cannabis
products and strains to the global market place as regulations
permit. Gene Simmons, music legend and media mogul, conveys the
vision of Invictus as the Chief Evangelist Officer.
Invictus operates two cannabis production sites under the Access to
Cannabis for Medical Purposes Regulations
(“ACMPR”) in Canada and has over 95,000 square
feet of cannabis production capacity at the licensed production
sites. The Company’s wholly owned subsidiary Acreage Pharms
Ltd. (“Acreage Pharms”), located in West-Central
Alberta on 150 acres, has approximately 40,000 square feet of
cannabis ready production with its recently completed Phase 2
expansion. The Company intends on expanding to 120,000 square
feet by the end of 2018 once Phase 3 is complete.
Invictus also owns 50% of AB Laboratories Inc. (“AB
Labs”), a licensed producer under the ACMPR located in
Hamilton, Ontario. AB Labs currently operates in a 16,000 square
foot facility and recently acquired a facility adjacent to the
existing property that will allow for a total of 56,000 square feet
of cultivation space expected to be ready for production by June
2018. During the first quarter of 2018 AB Labs submitted a
secondary license to Health Canada for a nearby property on 100
acres under the name AB Ventures Inc. (“AB
Ventures”).
Combined, the licensed producers owned by Invictus expect to have
approximately 200,000 square feet of cannabis production capacity
by the end of 2018 and 520,000 square feet of cannabis production
capacity by the end of 2019.
In addition to the ACMPR licenses, the Company has an 82.5%
investment in Future Harvest Development Ltd. a high quality
Fertilizer and Nutrients manufacturer based in Kelowna,
British Columbia that has been in operation for over 20 years under
the brand Plant Life Products and Holland Secret.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
In the United States
Terry Wills
twills@willscom.com
310-877-1458
Cautionary Note Regarding Forward-Looking Statements: This release
includes certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws or forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. All statements in this news release, other than
statements of historical facts, including statements regarding
future estimates, plans, objectives, timing, assumptions or
expectations of future performance, including the development of
additional cannabis strains, the potential production capacity of
AB Labs, AB Ventures and Acreage Pharms, the completion of AB
Ventures and Acreage Pharms’ production facilities, the granting of
regulatory approval and anticipated timing of AB Labs reaching full
production capacity, the granting of AB Labs secondary license, the
granting of a sales license under the ACMPR to Acreage Pharms,
expected sales of inventory and the legalization of the
recreational use of marijuana in Canada in 2018 are forward-looking
statements and contain forward-looking information. Generally,
forward-looking statements and information can be identified by the
use of forward-looking terminology such as “intends” or
“anticipates”, or variations of such words and phrases or
statements that certain actions, events or results “may”, “could”,
“should”, “would” or “occur”. Forward-looking statements are based
on certain material assumptions and analysis made by the Company
and the opinions and estimates of management as of the date of this
press release, including that Acreage Pharms will be successful in
developing additional cannabis strains, that AB Labs will be
successful in reaching its potential production capacity on the
timeline expected by the Company, AB Ventures and Acreage Pharms’
production facilities will be completed as anticipated, regulatory
approval will be granted as anticipated, AB Labs will reach full
production capacity on the timeline anticipated by the Company, AB
Labs will be granted its secondary license on the terms and
timeline anticipated by the Company, no unforeseen construction
delays will be experienced, Acreage Pharms will be granted its
sales license under the ACMPR on the terms and timeline anticipated
by the Company, expected sales of inventory will be met and the
legalization of the recreational use of marijuana in Canada will
occur as expected. These forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, level of activity, performance
or achievements of the Company to be materially different from
those expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, Acreage Pharms
will not be successful in developing additional cannabis strains
or, if developed, such strains will not have the benefits
anticipated by the Company, AB Labs will not be successful in
reaching its potential production capacity, AB Ventures and Acreage
Pharms’ production facilities will not be completed as anticipated,
construction delays, regulatory approval will not be granted as
anticipated and therefore, the anticipated timing of AB Labs
reaching full production capacity will be delayed, AB Labs not be
granted their secondary license, Acreage Pharms will not be
granted its sales license under the ACMPR, licenses or approvals
being granted on terms or timelines that are materially worse than
expected by the Company, expected sales of inventory will not be
met and the legalization of the recreational use of marijuana in
Canada will not occur at all or as expected. Although
management of the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements or forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements and forward-looking
information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company
does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Sep 2023 to Sep 2024